4.3 Article

Intestinal Microbiota-Produced Trimethylamine-N-Oxide and Its Association With Coronary Stenosis and HIV Serostatus

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0000000000000937

Keywords

HIV; trimethylamine-N-oxide; coronary artery disease

Funding

  1. NHLBI [RO1 HL095129]
  2. NIAID [P30AI094189]
  3. National Institute of Allergy and Infectious Diseases (NIAID)
  4. National Cancer Institute (NCI)
  5. JHU CTSA [UL1 TR 001079]
  6. Esperion
  7. Procter Gamble
  8. Abbott
  9. Astra Zeneca
  10. Cleveland Heart Lab
  11. Pfizer Inc.
  12. Roche
  13. Takeda

Ask authors/readers for more resources

Recent evidence has shown a complex relationship between the gut microbiota, dietary nutrients, and cardiovascular disease (CVD). Trimethylamine-N-oxide (TMAO) production, initiated by the microbiota, has been associated with CVD events. We sought to test if this association exists in HIV-infected persons. After adjusting for aspirin use and CVD risk factors, HIV-infected men were more likely to have coronary stenosis in the second and third TMAO quartiles compared with the first quartile, but did not differ significantly in the fourth quartile. We found an inverted U-shaped association between TMAO levels and the presence of coronary artery stenosis among HIV-infected men.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available